Hypermarcas (OTCMKTS:HYPMY) Upgraded to “Strong-Buy” at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Hypermarcas (OTCMKTS:HYPMY) to a strong-buy rating in a research note released on Monday,Zacks.com reports.

Separately, Zacks Research raised Hypermarcas to a “hold” rating in a report on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, Hypermarcas presently has a consensus rating of “Buy”.

Hypermarcas Stock Down 2.9%

HYPMY opened at $4.04 on Monday. Hypermarcas has a 52 week low of $3.71 and a 52 week high of $5.50. The business has a 50 day moving average price of $4.18 and a two-hundred day moving average price of $4.39. The company has a market cap of $2.84 billion, a PE ratio of 8.41 and a beta of 0.71.

Hypermarcas (OTCMKTS:HYPMY) last announced its earnings results on Wednesday, April 29th. The company reported $0.10 earnings per share for the quarter. The company had revenue of $383.13 million for the quarter. Hypermarcas had a return on equity of 14.08% and a net margin of 19.41%. As a group, sell-side analysts expect that Hypermarcas will post 0.53 EPS for the current fiscal year.

Hypermarcas Company Profile

Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.